Blue Cross Blue Shield of Michigan

A nonprofit corporation and independent licensee of the Blue Cross and Blue Shield Association

Submit medical drug prior authorization requests online

As part of our efforts to make the prior authorization (PA) process more efficient, we're encouraging prescribers register and use our Web-based system when prescribing medical drugs for commercial members. This new application gives providers the ability to submit forms electronically and the ability to lookup the status of their medical drug PA request.

In-state Providers

In order to be able to submit your prior authorization requests electronically, you will need to:

- Become a registered Availity user by clicking the following hyperlink, **availity.com/bcbsm**, and following the steps.

To request a drug prior authorization, please go to bcbsm.com and follow these easy steps:

Log into the Availity

- Navigate to **availity.com**, and enter your provided username and password
- Click the Payer Spaces drop down and select BCBSM BCN icon
- Scroll down the page and select the appropriate Novologix link for your member

Complete the Prior Authorization Request

- To login to Novologix, enter your User ID and Password
- Click the Authorizations drop down and select Create Authorization
- Enter in the members specific details and select the correct member on contract
- Complete the required fields and select the correct drug product in the Authorization Lines section
- Click Submit and complete the question to request prior authorization

Out-of-State Providers

In order to be able to submit your prior authorization requests electronically, you will need to:

- Access the Electronic Provider Access (EPA) via local Blues Plan
- Download the Registration form for electronic access from the Medical Prior Authorization Review link
  AND
- Submit the Registration form with a completed Medication Authorization Request Form (MARF) via fax or mail
- For additional information or instructions, please refer to the e-Learning Training Modules in the Provider Secure Services page OR contact the Help Desk at 877-258-3932

Disclaimer: Access is only available to registered users. A valid individual NPI is required for registration.

Blue Cross Blue Shield/Blue Care Network of Michigan
Medication Authorization Request Form
Tezspire™ (tezepelumab-ekko)
HCPCS CODE: J2356

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for Tezspire™. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION
Name	**Name**
ID Number	**Specialty**
D.O.B. ☐Male ☐Female	**Address**
Diagnosis	**City /State/Zip**
Drug Name	**Phone/Fax: P**: ( ) - **F**: ( ) -
Dose and Quantity	**NPI**
Directions	**Contact Person**
Date of Service(s)	**Contact Person Phone / Ext.**

STEP 1: DISEASE STATE INFORMATION

1. Is this request for: ☐ Initiation ☐ Continuation ***Date patient started therapy***: ________________

2. Please provide the NPI number for the place of administration: ____________________________________

3. **Initiation AND Continuation of therapy:**
   a. Please check the patient's diagnosis**:** ☐ Severe asthma ☐ Other: _______

   b. Which treatment(s) did not adequately control the patient's severe asthma symptoms after a trial of at least 3 months?
   ☐ Systemic corticosteroid: __________________ Date: *Start:* ________ *End:* _______
   ☐ High dose inhaled corticosteroids: __________________ Date: *Start:* ________ *End:* _______
   ☐ Long acting beta2-agonist: __________________ Date: *Start:* ________ *End:* _______
   ☐ Leukotriene receptor antagonist: __________________ Date: *Start:* ________ *End:* _______
   ☐ Combination asthma inhaler with a HIGH dose corticosteroid and a long acting beta agonist: ___________ Date: *Start:* _______ *End:* _______
   ☐ Combination asthma inhaler with a MEDIUM dose corticosteroid and a long acting beta agonist: ________ Date: *Start:* _______ *End:* _______
   ☐ Long acting muscarinic antagonist (LAMA): ________ Date: *Start:* ___________ *End:* ______________
   ☐ Other: ______________________________ Date: *Start:* ___________ *End:* ___________

   c. Is the patient currently receiving and will continue to receive a standard of care regimen for their diagnosis with Tezspire?
   ☐ Yes ☐ No Comment: ______________________________

   d. Will the patient be using Tezspire in combination with other biologic agents (for example: Xolair®, Nucala® or Fasenra™)?
   ☐ Yes ☐ No Comment: ______________________________

4. **Continuation request:** (please answer above questions as well): **Tezspire start date**: ______________________________
   a. Have the patient's signs and symptoms improved with Tezspire?
   ☐ Yes ☐ No Comment: ______________________________

Please add any other supporting medical information necessary for our review

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

☐ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name **Physician Signature** **Date**

Step 2 Checklist	☐ Form Completely Filled Out ☐ Attach Chart Notes	☐ Attach Diagnostic Tests
Step 3 Submit	**By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979**	**By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320**

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.